Survey on Minimal Residual Disease (MRD) Measurement in Multiple Myeloma

Survey on Minimal Residual Disease (MRD) Measurement in Multiple Myeloma - Survey on Minimal Residual Disease (MRD) Measurement in Multiple Myeloma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052475

Enrollment

150

Registered

2023-10-12

Start date

2023-06-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who meet all of the following inclusion criteria will be included: 1_Belong to the department of hematology 2_Work at a hospital (with 80 beds or more) 3_Treated "at least 2 patients with multiple myeloma in the last year" or "at least 1 patient per month" 4_Agreed to participate in the survey

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
To analyze the actual status of MRD measurement and its issues in the treatment of multiple myeloma and clarify unmet medical needs 1_Whether or not minimal residual disease (MRD) is measured 2_Whether or not imaging tests (PET/CT, MRI) are performed 3_Reasons for not measuring MRD 4_MRD measurement method 5_Criteria (detection sensitivity) 6_Purpose of measuring 7_Frequency of measurement	—

Secondary

Measure	Time frame
I.To clarify the prospects for the MRD measurement method as a prognostic factor in the future II.To provide a basis for future evidence generation activities 1_Purpose of MRD measurement 2_What is needed to promote MRD measurement 3_Challenges of imaging tests	—

Countries

Japan

Contacts

Public ContactTomoyuki Kusaka

Social Survey Research Information Co., Ltd. Healthcare BI & MA Service Division Health Outcomes Research

HOR@ssri.com03-6709-9710

Outcome results